06/29/2013
Tags:
Assay Automation,
Clinical Trials,
IST PartnershipsAdvanced automation of PBMC freezing (cryopreservation) and cell thawing improved the quantity and quality of PBMC yields and viability. through a partnership between ImmunoSite Technologies and MéCour.

05/07/2012
Tags:
Assay Automation,
Assay Standardization,
Biomarker,
Biotech,
Cell Mediated Immune Assays,
Drug Development,
Immune Monitoring,
PharmaThe need to implement robust biomarkers in clinical trials has never been greater, and such efforts can be easily compromised by reagent instability or simple human error during assay set-up. Many biotechnology and pharmaceutical companies are introducing efforts to conduct biomarker studies under more rigorous settings, and the use of plates or tubes pre-loaded with stimulation or staining reagents could be of value for studies that involve flow cytometry.
The value of this approach is that it lends itself to assay automation easily and safeguards against omission or erroneous addition of bulk liquid formulations of PMA and ionomycin to the reaction vessel (i.e., plate or tube) and also lends itself to extended stability/shelf-life of these reagents. On the basis of this initial success, we plan to expand our evaluation of lyophilized reagents so that they can be incorporated into our clinical biomarker campaigns as appropriate.

08/23/2011
Tags:
Assay Automation,
Assay Standardization,
Biotech,
Clinical Trials,
Drug Development,
Immune MonitoringThe identification and application of correlates of immune response can enable significant time and money savings especially in clinical trial settings for vaccine and biologic R&D. To download, please fill in the form below: [email-download download_id="2" contact_form_id="3"] Share this:

01/10/2011
Tags:
Assay Automation,
Assay Standardization,
Biomarker,
clinical research,
Clinical Trials,
Drug Development,
Immune MonitoringReaders gain an understanding of the details and the high level considerations of assay qualification for difficult cell-based assays. The level of optimization described for cell-based assays lends itself to biomarker assay automation which can be used for biomarker qualification and validation studies to the satisfaction of the FDA, EMEA, and other regulatory agencies.
Cell-based assay platforms covered are flow cytometry, intracellular cytokine ICS, immunophenotyping, elispot, IHC, cylex, neutralization bioassays, and endpoint assays.
